Inhibitory effect of yogurt on aberrant crypt foci formation in the rat colon and colorectal tumorigenesis in RasH2 mice.
The inhibitory effects of yogurt consisting of milk fermented by Lactobacillus delbrueckii subsp. bulgaricus strain 2038 and Streptococcus salivarius subsp. thermophilus strain 1131 on formation of colonic aberrant crypt foci (ACF) in rats and also on development of colorectal tumors in transgenic mice harboring human prototype c-Ha-ras genes (rasH2 mice) were examined. F344 rats and rasH2 mice were fed commercial diet containing freeze-dried yogurt or starter medium (non-fermented milk). Rats were inoculated orally with heterocyclic amine 2-amino-methyl-6-phenylimidazo[4,5-b]pyridine hydrochloride (PhIP) for two weeks. The rats were necropsied 14 days after the PhIP treatment, and ACF in the colon and rectum were counted. RasH2 mice were injected with 1,2-dimethylhydrazine dihydrochloride (DMH) for 20 weeks. Three weeks after the last injection of DMH, rasH2 mice were necropsied to determine the number and the size of colorectal tumors. Yogurt supplementation in diet significantly reduced the number of ACF and aberrant crypts (ACs) in rats fed control diet (P<0.01), but not in rats fed non-fermented milk diet. On the other hand, rasH2 mice receiving the yogurt-supplemented diet had significantly reduced numbers of tumors induced by DMH compared with those fed the non-fermented milk-supplemented diet (P<0.05). These results demonstrate that the yogurt used in this study appears to have tumor-suppressing properties, and rasH2 mice are a useful model for the evaluation of antitumor activities of foods.
Narushima
Seiko
S
Laboratory of Veterinary Public Health, The University of Tokyo, Bunkyo-ku, Tokyo, Japan.
Sakata
Tadashi
T
Hioki
Kyoji
K
Itoh
Toshio
T
Nomura
Tatsuji
T
Itoh
Kikuji
K
D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage*; D002273:Carcinogens / Q000633:toxicity; D003106:Colon / Q000187:drug effects* / Q000473:pathology; D015179:Colorectal Neoplasms / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D011905:Genes, ras / Q000235:genetics; D006801:Humans; D007093:Imidazoles / Q000633:toxicity; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D011230:Precancerous Conditions / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D051381:Rats; D011916:Rats, Inbred F344; D012007:Rectum / Q000187:drug effects / Q000473:pathology; D015014:Yogurt; D018631:ras Proteins / Q000235:genetics
D016588:Anticarcinogenic Agents; D002273:Carcinogens; D007093:Imidazoles; C049584:2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine; C513254:Rras protein, mouse; D018631:ras Proteins